217 related articles for article (PubMed ID: 23983430)
1. Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.
Tamè M; Buonfiglioli F; Del Gaudio M; Lisotti A; Cecinato P; Colecchia A; Azzaroli F; D'Errico A; Arena R; Calvanese C; Quarneti C; Ballardini G; Pinna AD; Mazzella G
World J Gastroenterol; 2013 Aug; 19(32):5278-85. PubMed ID: 23983430
[TBL] [Abstract][Full Text] [Related]
2. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
[TBL] [Abstract][Full Text] [Related]
3. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
[TBL] [Abstract][Full Text] [Related]
5. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
6. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
7. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
8. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
9. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
10. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
[TBL] [Abstract][Full Text] [Related]
12. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
[TBL] [Abstract][Full Text] [Related]
13. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460
[TBL] [Abstract][Full Text] [Related]
14. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
[TBL] [Abstract][Full Text] [Related]
15. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
16. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Bizollon T; Adham M; Pradat P; Chevallier M; Ducerf C; Baulieux J; Zoulim F; Trepo C
Transplantation; 2005 Feb; 79(3):325-9. PubMed ID: 15699763
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Nair S; Lipscomb J; Eason J
Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
